Drug intelligence / Profile preview

SBRX11

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX11 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of resistant malaria and associated symptoms, including intermittent fevers, malaise, and lethargy. It is part of the company's SBRX series of natural therapeutics derived from a proprietary database of medicinal plants. The drug is designed to undergo rigorous clinical testing to validate its efficacy as a natural alternative to conventional antimalarials, leveraging the expertise of the company's leadership in sub-Saharan malaria research.

Beyond the preview

Go deeper on SBRX11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX11.

Explore the full profile